LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · Real-Time Price · USD
0.7890
+0.0231 (3.02%)
Aug 14, 2025, 2:25 PM - Market open
LakeShore Biopharma Balance Sheet
Financials in millions CNY. Fiscal year is April - March.
Millions CNY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Cash & Equivalents | 28.08 | 246.35 | 370.11 | 271.07 | 390.46 |
| Cash & Short-Term Investments | 28.08 | 246.35 | 370.11 | 271.07 | 390.46 |
| Cash Growth | -88.60% | -33.44% | 36.54% | -30.58% | - |
| Accounts Receivable | 500.92 | 444.16 | 463.05 | 308.56 | 214.5 |
| Other Receivables | 0.87 | 2.99 | 5.21 | 4.18 | 30.54 |
| Receivables | 501.79 | 447.15 | 468.27 | 312.74 | 248.01 |
| Inventory | 229.28 | 205.09 | 192.14 | 177.15 | 92.9 |
| Restricted Cash | 79.4 | 0.2 | 0.26 | - | - |
| Other Current Assets | 3.66 | 4.38 | 5.2 | 3.81 | 1.84 |
| Total Current Assets | 842.22 | 903.17 | 1,036 | 764.76 | 733.2 |
| Property, Plant & Equipment | 414.35 | 480.62 | 582.89 | 565 | 253.45 |
| Other Intangible Assets | 72.85 | 71.25 | 78.06 | 80.72 | 83.78 |
| Long-Term Deferred Tax Assets | 27.95 | 23.63 | 1.91 | 3.04 | 7.98 |
| Other Long-Term Assets | 10.3 | 34.36 | 20.92 | 28.23 | 88.77 |
| Total Assets | 1,368 | 1,513 | 1,720 | 1,442 | 1,167 |
| Accounts Payable | 49.55 | 67.77 | 80.44 | 30.81 | 16.38 |
| Accrued Expenses | 253.55 | 247.59 | 204.29 | 166.3 | 167.57 |
| Short-Term Debt | 370.86 | 296.73 | 185.07 | 111.1 | - |
| Current Portion of Long-Term Debt | 19.58 | 21.81 | 8.67 | 0.63 | - |
| Current Portion of Leases | 0.46 | 5.16 | 4.75 | 4.32 | 3.79 |
| Current Unearned Revenue | 1.46 | 2.02 | 2.3 | 2.3 | 2.12 |
| Other Current Liabilities | 129.29 | 161.15 | 173.25 | 160.46 | 155.18 |
| Total Current Liabilities | 824.75 | 802.23 | 658.76 | 475.91 | 345.04 |
| Long-Term Debt | 23.5 | 98.98 | 293.79 | 253.93 | 1.1 |
| Long-Term Leases | - | 1.78 | 6.35 | 10.61 | 13.55 |
| Long-Term Unearned Revenue | 16.21 | 20.28 | 23.61 | 30.05 | 30.88 |
| Other Long-Term Liabilities | 3.44 | 4.55 | 8.79 | - | - |
| Total Liabilities | 867.91 | 927.82 | 991.3 | 770.5 | 390.58 |
| Common Stock | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 |
| Additional Paid-In Capital | 2,964 | 2,951 | 2,657 | 808.5 | 800.81 |
| Retained Earnings | -2,407 | -2,308 | -1,874 | -1,591 | -1,354 |
| Comprehensive Income & Other | -57.27 | -58.18 | -54.41 | 83.09 | 44.22 |
| Total Common Equity | 499.75 | 585.21 | 728.45 | -698.97 | -508.86 |
| Shareholders' Equity | 499.75 | 585.21 | 728.45 | 671.25 | 776.6 |
| Total Liabilities & Equity | 1,368 | 1,513 | 1,720 | 1,442 | 1,167 |
| Total Debt | 414.4 | 424.46 | 498.63 | 380.59 | 18.44 |
| Net Cash (Debt) | -386.32 | -178.11 | -128.52 | -109.52 | 372.02 |
| Net Cash Per Share | -20.16 | -16.66 | -20.80 | -17.71 | 60.17 |
| Filing Date Shares Outstanding | 41.21 | 19.08 | 9.31 | 352.49 | 6.18 |
| Total Common Shares Outstanding | 20.77 | 19.02 | 9.31 | 353.31 | 6.18 |
| Working Capital | 17.47 | 100.94 | 377.22 | 288.85 | 388.16 |
| Book Value Per Share | 24.07 | 30.76 | 78.28 | -1.98 | -14.40 |
| Tangible Book Value | 426.9 | 513.96 | 650.4 | -779.69 | -592.64 |
| Tangible Book Value Per Share | 20.56 | 27.02 | 69.89 | -2.21 | -16.77 |
| Machinery | 442.87 | 529.04 | 464.97 | 408.06 | 354.28 |
| Construction In Progress | 287.88 | 255.11 | 309.95 | 318 | 40.16 |
| Leasehold Improvements | 2.39 | 4.86 | 5.6 | 4.39 | 3.89 |
Updated Aug 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.